/PRNewswire/ OnQuality Pharmaceuticals ("OnQuality"), an oncology company developing targeted supportive therapies to address unmet needs in oncodermatology.
Share this article
Share this article
SEATTLE, May 19, 2021 /PRNewswire/ OnQuality Pharmaceuticals ( OnQuality ), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021, and an oral presentation at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Annual Meeting, being held virtually from June 24-26, 2021. The abstracts for both presentations include an update on the ongoing Phase II clinical trial and are both titled A Study to Investigate OQL011 on VEGFR Inhibitor-Associated